Contemporary management of breast cancer

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 1, 2002, Pages 173-188

  Chung, Maureen A ^a,b   Wazer, David ^b,c,d   Cady, Blake ^a,b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; TUMOR VOLUME;

EID: 0036187484     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(03)00060-3     Document Type: Review

References (73)

1. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
2. Subclinical ductal carcinoma in situ of the breast: Treatment with conservative surgery and radiotherapy
3. Axillary lymph node metastasis in patients with small carcinomas of the breast: Is accurate prediction possible?
4. Predictors of axillary lymph node metastasis in patients with T1 breast carcinoma
5. Non-invasive ductal carcinoma of the breast: The relevance of histologic categorization
6. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Breast Cancer Trial 10853
7. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis
8. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy
9. New therapeutic possibilities in primary invasive breast cancer
10. Basic principles in surgical oncology
11. CRC (Kings/Cambridge) trial for early breast cancer. Detailed uptake of the tenth year
12. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ
13. Extent of excision width required in breast conserving surgery for ductal carcinoma in situ
14. Axillary lymph node dissection: Is it required in Tla breast cancer?
15. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary dissection?
16. Trends in breast cancer incidence and presentation in a population screened for breast cancer
17. Non-palpable lesions of the breast detected by mammography-review of the 1182 consecutive histologically confirmed cases
18. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node negative cancer
19. Ductal carcinoma in situ of the breast: Correlation of pathologic and mammographic features with extent of disease
20. Axillary node status in nonpalpable breast cancer
21. Early breast cancer trialists collaborative group: Favorable and unfavorable effects on long term survival of radiotherapy for early breast cancer: An overview of the randomised trials
22. Incidence and treatment for ductal carcinoma in situ of the breast
23. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program
24. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol 17: Five-year observations concerning lobular carcinoma in situ
25. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
26. Significance of ipsilateral breast recurrance after lumpectomy
27. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
28. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
29. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: Intraductal carcinoma
30. Tamoxifen in treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
31. Significance of ipsilateral breast recurrence after lumpectomy
32. Lobular carcinoma in situ: A rare form of mammary cancer
33. Randomised controlled trial of conservation therapy for breast cancer: 6 Year analysis of the Scottish trial
34. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers
35. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast
36. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ)
37. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast
38. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: Results of a randomized study
39. Management of the axilla in patients with breast cancers 1 centimeter or smaller
40. Partial mastectomy without radiation is adequate treatment for patients with stages 0 and 1 carcinoma of the breast
41. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma
42. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853
43. Mammographically detected duct carcinoma in situ: Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
44. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomized trial
45. Axillary lymph node metastasis associated with small invasive breast carcinomas
46. Factors associated with local breast cancer recurrence after lumpectomy alone: Postmenopausal patients
47. The value of axillary dissection in Tla breast cancer
48. Anaphylaxis to patent blue dye during sentinel lymph node biopsy for breast cancer
49. Indications for axillary dissection in T1 breast cancer
50. The impact of histopathology on nodal metastasis in minimal breast cancer
51. Current management of lobular carcinoma in situ of the breast
52. Atypical ductal and lobular hyperplasia and breast cancer risk
53. Factors affecting the incidence of lymph node metastases in small cancers of the breast
54. Predictive factors associated with axillary lymph node metastases in Tla and Tlb breast carcinomas: Analysis in more than 900 patients
55. Incidence of axillary lymph node metastasis in Tla and Tlb breast carcinoma
56. Infiltrating breast carcinoma smaller than 0.5 centimeters: Is lymph node dissection necessary?
57. Neoadjuvant chemotherapy for breast cancer
58. A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer
59. Predictors of axillary lymph node metastasis in T1 breast carcinoma
60. A prognostic index for ductal carcinoma in situ of the breast
61. The influence of margin width on local control in patients with ductal carcinoma in situ (DCIS) of the breast
62. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: A prospective study
63. Long term follow-up of women with ductal carcinoma in situ treated with breast conservation surgery: The effect of age
64. Breast conservation is a safe method in patients with small cancer of the breast: Long-term results of three randomised trials on 1973 patients
65. Quadrantectomy versus lumpectomy for small size breast cancer
66. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast
67. Impact of young age on outcome in patients with ductal carcinoma in situ treated with breast conserving surgery
68. Using autopsy series to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast: How much more breast cancer can we find?
69. Outcomes and factors impacting local recurrence of ductal carcinoma in situ
70. Axillary lymph node metastasis in stage Tla breast cancer: A pathologic review of 82 patients
71. Lymph node metastasis from ductal carcinoma in situ with microinvasion